Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 CAD | -6.02% | -1.27% | +457.14% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+457.14% | 128M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.32% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR